Interleukin-17A Inhibitor Secukinumab Treatment in HIV-Positive Psoriasis Patient: A Case Report.
Jian GongWeiwei WuLiguo QiuXi WangJianwei BaoJinjing WangLifang ChengZhiyuan FuFengming HuPublished in: Clinical, cosmetic and investigational dermatology (2022)
Psoriasis is an immune-mediated chronic inflammatory dermatosis influenced by hereditary and environmental factors. Human immunodeficiency virus (HIV) infection affects the immune system and exacerbates psoriatic lesions. We report the case of a 33-year-old male patient diagnosed with psoriasis vulgaris, psoriatic arthritis and HIV infection. Acitretin capsules, etanercept and high-active antiretroviral therapy (HAART) were effective. Two months after etanercept was discontinued, his condition worsened. After switching to secukinumab combined with HAART, the symptoms of psoriatic arthritis resolved rapidly after four weeks, with a Disease Activity Index for Psoriatic Arthritis score of 0. The time to achieve psoriasis area and severity index 40, 75, 90, and 100 were 2, 4, 8, and 29 weeks. The treatment was maintained for 1 year with no adverse reactions. Regarding the stable CD4 + T lymphocyte count and the viral load, administering anti-IL-17 monoclonal antibodies is an effective treatment option for psoriasis patients.
Keyphrases
- antiretroviral therapy
- human immunodeficiency virus
- hiv positive
- ankylosing spondylitis
- disease activity
- rheumatoid arthritis
- hiv infected patients
- hiv infected
- rheumatoid arthritis patients
- systemic lupus erythematosus
- hiv aids
- hepatitis c virus
- juvenile idiopathic arthritis
- oxidative stress
- end stage renal disease
- ejection fraction
- south africa
- emergency department
- case report
- peritoneal dialysis
- replacement therapy
- preterm birth
- depressive symptoms
- combination therapy
- patient reported